1.	A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML18527, NCT00121836
2.	Phase II/III Randomized Study of a New Paclitaxel Formulation Given by 3-Hour vs 96-Hour Infusion in Women with Refractory Metastatic Breast Cancer (Summary Last Modified 11/95) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: any age Sponsor: Other Protocol IDs: MAOP-1195, NCI-V95-0749
3.	Phase III Study of a 3-Hour Infusion of a New Paclitaxel Product in Refractory Ovarian Cancer, with a Phase II Crossover to a 96-Hour Infusion at Progression (Summary Last Modified 12/95) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: MAOP-7195, NCI-V95-0750
4.	Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without SCH 58500 in Patients with Newly Diagnosed Stage III Ovarian Epithelial or Primary Peritoneal Cancer With No Greater Than 2 cm Residual Disease Following Surgery (Summary Last Modified 07/2001) Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SPRI-C/I98-102, SPRI-C98-102, NCI-V99-1544, NCT00003880
5.	Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without BMS-275291 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAN-NCIC-BR18, BMS-CA161-003, NCT00006229, BR18
6.	Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without Bevacizumab in Patients With Advanced, Metastatic, or Recurrent Non-Squamous Cell Non-Small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-4599, CALGB-E4599, E4599, NCT00021060
7.	Phase II/III Randomized Trial of DOX vs TAX vs DOX/TAX/G-CSF in Patients with Metastatic Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Completed Age: any age Sponsor: NCI Protocol IDs: E-1193, NCCTG-923252, SWOG-9332, E-10292, E1193
8.	Phase II/III Randomized Study of Paclitaxel and Carboplatin With Versus Without Cediranib Maleate in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CAN-NCIC-BR24, ZENECA-CAN-NCIC-BR24, NCT00245154, BR24, FHCRC-6107, UWCC-UW 6107, UWCC- 06-2707-H/B
9.	Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: NBCG10, REK 378-04-03133, NMA 03-07568, NCT00201435
10.	A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: CA139-384, NCT00337532
11.	Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 40 to 75 Sponsor: Other Protocol IDs: Hamamatsu 18-66, NCT00752115
12.	Phase III Randomized Study of G-CSF Priming Prior to Neoadjuvant TAX/CBDCA Followed by a Phase I Dose-Seeking Study of TAX/CBDCA During Definitive Radical Thoracic Irradiation for Stages IIIB/Bulky IIIA Nonsmall Cell Lung Cancer (Summary Last Modified 12/95) Phase: Phase III, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: FCCC-94001, NCI-V94-0479
13.	Phase III Randomized Study of High-Dose Paclitaxel Administered as a 3-Hour vs a 24-Hour Infusion in Women with Metastatic or Locally Advanced Breast Cancer (Summary Last Modified 11/2000) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NSABP-B-26
14.	Phase III Randomized Study of Paclitaxel Administered as a 3-Hour Infusion at Three Different Doses in Women with Recurrent Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CLB-9342, CALGB-9342
15.	Phase III Randomized Study of Adjuvant CA (Cyclophosphamide/Doxorubicin) Comparing Standard- vs Intermediate- vs High-Dose Doxorubicin, with vs without Subsequent Paclitaxel, in Women with Node-Positive Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: over 18 Sponsor: NCI Protocol IDs: CLB-9344, E-C9344, NCCTG-943051, SWOG-9410, INT-0148
16.	Phase III Randomized Study of Paclitaxel (Taxol) and Cisplatin (CDDP) Alone vs Taxol/CDDP with Interval Secondary Cytoreductive Surgery for Suboptimally Resected Stage III Ovarian Epithelial Carcinoma Phase: Phase III Type: Treatment Status: Closed Age: any age Sponsor: NCI Protocol IDs: GOG-152, NCT00002568, GOG-0152
17.	Phase III Randomized Study of TAX/CDDP vs CTX/CDDP in Patients with Advanced Epithelial Ovarian Cancer Phase: Phase III Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: EORTC-55931, CAN-NCIC-OV10, SCOTTISH-GYN-G42, SGCSG-NOCOVA-9410, OV10
18.	Phase III Randomized, Open-Label, Multicenter Study of Topotecan vs Paclitaxel as Single-Agent, Second-Line Therapy for Platinum-Refractory Advanced Epithelial Ovarian Carcinoma (Summary Last Modified 11/94) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: SB-104864/039, NCI-V94-0490
19.	Phase III Randomized Study of Platinum Compound and Paclitaxel in Optimal Stage III Ovarian Epithelial Cancer: Cisplatin and Paclitaxel (24-Hour Continuous Infusion) vs Carboplatin and Paclitaxel (3-Hour Infusion) Phase: Phase III Type: Treatment Status: Completed Age: any age Sponsor: NCI Protocol IDs: GOG-0158, GOG-0158
20.	Phase III Randomized Study of High-Dose CBDCA/CTX with G-CSF Followed by Standard-Dose TAX vs High-Dose TAX with G-CSF for Nonpalpable Suboptimal Stage III Ovarian Epithelial Carcinoma (Summary Last Modified 08/98) Phase: Phase III Type: Treatment Status: Closed Age: adult Sponsor: NCI Protocol IDs: SWOG-9249
21.	Phase III Randomized Study of CBDCA/TAX Administered for 3 vs 6 Courses for Selected Stages IA-C and Stages IIA-C Ovarian Epithelial Cancer Phase: Phase III Type: Treatment Status: Completed Age: any age Sponsor: NCI Protocol IDs: GOG-0157, GOG-0157, GOG-0157
22.	Phase III Randomized Study of Docetaxel Versus Paclitaxel in Women With Metastatic or Locally Advanced, Inoperable Adenocarcinoma of the Breast Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AVENTIS-56976-TAX-311, RP-56976-TAX-311, NCI-V95-0680, NCT00002662
23.	Phase III Randomized Study of Chemotherapy with vs without Monoclonal Antibody HER2 in Women with Metastatic Breast Cancer Overexpressing HER2/neu and Previously Untreated with Cytotoxic Chemotherapy (Summary Last Modified 09/95) Phase: Phase III Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: GENENTECH-HO648G, NCI-V95-0714
24.	Phase III Randomized Study of Paclitaxel vs No Further Chemotherapy Following Doxorubicin/Cyclophosphamide for Resected Node-Positive Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 to 78 Sponsor: NCI Protocol IDs: NSABP-B-28
25.	Phase III Randomized Study of Losoxantrone/Paclitaxel/G-CSF vs Paclitaxel Alone in Women with Stage IV Breast Cancer (Summary Last Modified 05/97) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DUP-941-017, NCI-V95-0785